Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s share price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$8.89 and traded as low as C$7.98. Fennec Pharmaceuticals shares last traded at C$7.98, with a volume of 401 shares.
Fennec Pharmaceuticals Trading Down 0.4 %
The business’s fifty day moving average price is C$8.89 and its 200 day moving average price is C$11.57. The company has a quick ratio of 10.17, a current ratio of 6.93 and a debt-to-equity ratio of 1,040.68. The firm has a market capitalization of C$217.19 million, a PE ratio of 159.00 and a beta of 0.46.
Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last announced its earnings results on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.67 by C($0.11). The firm had revenue of C$34.21 million for the quarter, compared to analyst estimates of C$14.19 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 6.33%. As a group, analysts expect that Fennec Pharmaceuticals Inc. will post 1.1958225 EPS for the current fiscal year.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Why Invest in 5G? How to Invest in 5G Stocks
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Transportation Stocks Investing
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.